- 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p<0.001)[1]
- All ranked secondary endpoints were met[1]
- These results reaffirm findings from the first Phase 3 induction study, U-ACHIEVE[1,2]
- Safety results were consistent with the previous Phase 3 induction study and the known profile of upadacitinib, with no new safety risks observed[1-6]
- Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as an oral therapy for moderate to severe ulcerative colitis and several other immune-mediated diseases[1,7-14]
PR Newswire
NORTH CHICAGO, Ill., Feb. 22, 2021
